Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Update

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) saw a large decline in short interest during the month of February. As of February 13th, there was short interest totaling 125,617 shares, a decline of 40.3% from the January 29th total of 210,405 shares. Approximately 0.2% of the company’s shares are sold short. Based on an average trading volume of 20,805 shares, the short-interest ratio is presently 6.0 days. Based on an average trading volume of 20,805 shares, the short-interest ratio is presently 6.0 days. Approximately 0.2% of the company’s shares are sold short.

Innate Pharma Price Performance

Shares of NASDAQ IPHA opened at $1.72 on Friday. Innate Pharma has a twelve month low of $1.57 and a twelve month high of $2.63. The company’s fifty day moving average is $1.75 and its 200-day moving average is $1.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Innate Pharma in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $5.00.

Institutional Investors Weigh In On Innate Pharma

Large investors have recently modified their holdings of the business. Millennium Management LLC bought a new position in shares of Innate Pharma during the 4th quarter valued at about $36,000. OLD Mission Capital LLC bought a new stake in Innate Pharma during the 4th quarter worth approximately $50,000. Finally, Jane Street Group LLC acquired a new stake in Innate Pharma during the 4th quarter worth approximately $162,000. 0.16% of the stock is currently owned by institutional investors.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.